Kalamazoo, MI, USA / WKZO | Everything Kalamazoo | 590 AM · 106.9 FM Apr 1, 2021 9:12 AM WARSAW (Reuters) - Poland's Mabion aims to start production of U.S. firm Novavax's coronavirus vaccine for Europe from the third quarter, representatives of the biotechnology company said. Mabion and Novavax last month signed a framework deal on the transfer of COVID-19 vaccine technology to Mabion's plant in central Poland, which was designed to produce a rare diseases drug yet to be registered. "The production of our core product is much more complicated (than vaccine)," Mabion board member Adam Pietruszkiewicz told Reuters. Mabion is adding equipment necessary to start Novavax vaccine production, not without problems, as access to such machines has been limited. It is taking advantage of Novavax's strong negotiation position with equipment suppliers.